Hinge Health, Inc.'s SEC filings document its public-company reporting as an emerging growth company operating a technology platform for musculoskeletal care. Its Form 8-K filings cover quarterly and annual financial results, furnished earnings releases, supplemental investor materials, non-GAAP financial measures and reconciliations, and Regulation FD disclosures.
The company’s filings also record governance and capital-structure matters, including proxy materials for director elections and auditor ratification, board appointments and committee assignments, share repurchase authorization, Class A common stock disclosures, and post-IPO lock-up matters. These documents provide formal disclosure on operating results, stockholder voting matters, board oversight, capital allocation and securities-related events.
Hinge Health, Inc. reported that Director, Executive Chairman and Co-Founder Gabriel Mecklenburg sold 200,000 common shares on October 12, 2026, with an aggregate market value of $20,580,000. In the prior three months, he also sold 150,000 shares for $13,982,805 on September 14 and 250,000 shares for $22,242,075 on September 11; both earlier sales are identified as 10b5-1 sales.
Hinge Health, Inc. (HNGE) lists 47,720 common shares to be sold by Officer James Budge, with an aggregate market value of $4,910,388.00 through Morgan Stanley Smith Barney LLC. The listed approximate sale date is October 12, 2026. The securities were acquired upon vesting of restricted stock units from May 21, 2025 through October 10, 2026. The past-three-month sales section lists 55,561 common shares sold on September 10, 2026, with an aggregate market value of $4,969,997.03, and labels those sales as 10b5-1 sales for James Budge.
Hinge Health, Inc. CEO & Co-Founder, director and ten percent owner Daniel Antonio Perez converted 4,100 Class B shares into 4,100 Class A shares on October 6, 2026, then sold 4,100 Class A shares at a weighted average $100.1978 per share. The sale was made under a Rule 10b5-1 plan adopted by Perez and his spouse on June 11, 2026. Following the transaction, Perez reported 9,774,572 Class B shares, excluding 3,777,002 performance-based restricted stock units. His spouse separately held 208,445 Class B shares and 35,470 Class A shares indirectly.
Hinge Health, Inc. (HNGE) reports Daniel Perez’s notice of a proposed sale of 4,100 common shares, with an aggregate market value of $403,235.00 and an approximate sale date of October 6, 2026. The shares are listed as acquired from the issuer through restricted stock units on May 21, 2025. The notice also lists 10b5-1 sales dated September 10, 2026, during the prior three months: Daniel Perez, 100,000 shares with reported proceeds of $8,944,950.00; and Suthasini Mogun, 150,000 shares with reported proceeds of $13,416,700.00.
Hinge Health, Inc. (HNGE) director Tyler Sloat received 175 shares of Class A common stock on October 5, 2026, upon settlement of fully vested restricted stock units. The reported per-share price was $92.5620. The RSUs were awarded in lieu of quarterly cash retainers, at Sloat’s election, under the company’s Non-Employee Director Compensation Program. He directly held 10,385 shares after the transaction.
Hinge Health, Inc. (HNGE) President James Pursley relinquished and had 831 shares of Class A Common Stock cancelled on October 1, 2026, in connection with federal and state tax withholding obligations from restricted stock unit vesting. In exchange, the company agreed to pay those obligations. Pursley reported 666,078 shares held directly after the transaction.
Hinge Health, Inc. Chief Financial Officer James Budge relinquished 4,614 Class A shares on October 1, 2026. The issuer canceled the shares in exchange for agreeing to pay federal and state tax withholding obligations resulting from restricted stock unit vesting. The reported price was $97.24 per share; Budge held 344,448 shares directly after the transaction.
Hinge Health, Inc. is the issuer in a notice stating that its 10% stockholder, Insight Venture Partners X (Co-Investors), L.P., proposes to sell 11,587 Class A shares for an aggregate market value of $1,135,526.00, with an approximate sale date of September 30, 2026. Raymond James & Associates, Inc. is listed as broker.
Hinge Health, Inc.’s 10% stockholder, Insight Venture Partners (Delaware) X, L.P., gives notice of a proposed sale of 77,248 Class A shares, with an aggregate market value of $7,570,304 and an approximate sale date of September 30, 2026. Raymond James & Associates, Inc. is listed as broker. The past-three-months sales list includes 49,064 Class A shares sold on August 10, 2026, for $4,490,209.71. Rashida Mitchell signed as a duly authorized representative of Raymond James & Associates, Inc. and attorney-in-fact for Insight Venture Partners (Delaware) X, L.P.
Hinge Health, Inc. (HNGE) is the issuer for a proposed sale by its 10% stockholder, Insight Venture Partners X, L.P., of 486,991 Class A shares with an aggregate market value of $47,725,118. The notice lists an approximate sale date of September 30, 2026, and reports 62,468,721 Class A shares outstanding. It also lists six sales by the partnership during the past three months.